Evidence map›Paper›PMID 38296627›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2024

[Research Progress of Granulocytic Myeloid-derived Suppressor Cells 
in Non-small Cell Lung Cancer].

Chaodan Yang, Rui Zhu, Yuting Zhang, Lisha Ying, Jiamin Wang, Pan Liu, Dan Su

Open access · greenAbstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chaodan YangSchool of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Rui ZhuDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute 
of Medicine, Chinese Academy of Sciences, Hangzhou 310022, China.
Yuting ZhangPostgraduate Training Base Alliance of Wenzhou Medical 
University, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Lisha YingDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute 
of Medicine, Chinese Academy of Sciences, Hangzhou 310022, China.
Jiamin WangSchool of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Pan LiuDepartment of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute 
of Medicine, Chinese Academy of Sciences, Hangzhou 310022, China.
Dan SuSchool of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Chinese Academy of Sciences · CNShanghai Institute of Materia Medica · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulocytic myeloid-derived suppressor cells (G-MDSCs) are one of the main subgroups of MDSCs, which are widely enriched in most cancers. It can inhibit the killing function of T-lymphocyte through the expression of arginase-1 (Arg-1) and reactive oxygen species (ROS), reshape the tumor immune microenvironment, and promote the occurrence and development of tumors. In recent years, more and more studies have found that G-MDSCs are significantly correlated with the prognosis and immunotherapy efficacy of patients with non-small cell lung cancer, and the use of drugs specifically targeting the recruitment, differentiation and function of G-MDSCs can effectively inhibit tumor progression. This article reviews the immunosuppressive effect of G-MDSCs in non-small cell lung cancer and the progress of related pathway targeting drugs.
.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMyeloid-Derived Suppressor CellsHumansImmunotherapyT-LymphocytesTumor MicroenvironmentGranulocytic myeloid-derived suppressor cellsImmune microenvironmentImmunotherapyLung neoplasmsTargeted therapy

Identifiers

PMID38296627
PMCPMC10895289
OpenAlexW4394739548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.